🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07078591
Recruiting Phase 2

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

NCT07078591 · tracked via the Priya Life Science China tracker
Sponsor
Beijing 302 Hospital
Phase
Phase 2
Started
2025-06-20
Last updated
2025-07-28

Condition(s) studied

Acute Myeloid Leukemia

Investigational drug(s) / intervention(s)

Venetoclax →Azacitidine (AZA) →Daunorubicin →Idarubicin(IDA)Cytarabine (Ara-C) →GPBMC infusion

Venetoclax: Given PO

Azacitidine (AZA): Given SC

Daunorubicin: Given IV

Idarubicin(IDA): Given IV

Cytarabine (Ara-C): Given IV

GPBMC infusion: HLA-mismatched donor GPBMC infusion

Study summary

The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>=18 years, male or female, non-limited by race or ethnicity. * No prior anti-acute leukemia treatment (including hypomethylators for leukemia or MDS) with the exception that prior hydroxyurea and/or leukapheresis are permitted. * Confirmed acute myeloid leukemia in accordance with WHO criteria with a WBC count \< 25 × 109/L. * Adequate hepatic function including alanine transaminase (ALT) and aspartate aminotransferase (AST )\<= 3 × upper limit of normal(ULN), and total bilirubin \<= 1.5 × ULN. * Adequate renal function including serum creatinine \<= 2 × ULN or CrCl\>= 40mL/min. * LVEF measured by echocardiogram is within the normal range (LVEF \> 50%). * The subject must have one donor who is \>= 18 years old and HLA matched at 0-7/10 loci (i.e., at least 3 HLA loci must be mismatched). In addition, the donor voluntarily donates hematopoietic stem cells and signs the consent form. * Each subject (or his/her legal representatives) must sign the Informed Consent Form (ICF), indicating that he/she understands the purpose and procedures of research, and is willing to participate in research. * Donor inclusion criteria: The donor meets the institution's criteria for related peripheral blood hematopoietic stem cell donors. The donor must be able to tolerate the cell separation and collection process, and sign the Informed Consent Form. Exclusion Criteria: * Acute promyelocytic leukemia, myeloid sarcoma, chronic myeloid leukemia accelerated phase and blast crisis. * Uncontrolled infection or hemorrhage. * Cardiovascular disease with clinical significance, such as uncontrolled or highly symptomatic cardiac arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to screening, or New York Heart Association (NYHA) function class 3 (moderate) or class 4 (severe) heart disease. * Uncontrolled autoimmune disease or requiring immunosuppression treatment. * History of severe blood infusion reaction. * Nursing women, women of childbearing potential with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception. * Psychiatric disorder or cognitive impairment that in the researcher's judgment would make the subject not likely to adhere to the protocol requirements. * Any major surgery within 4 weeks before enrollment. * Life-threatening illness other than AML or uncontrolled intercurrent illness.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital Beijing China Recruiting

On this site

📄 Venclexta (venetoclax) drug profile →

More Beijing 302 Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07078591 on ClinicalTrials.gov ↗ ← All trials in China